治疗由型肝炎病毒引起的自身免疫性肝炎
Eleni Gigi1, Vasileios Lagopoulos2, Aris Liakos3
1Hepatology Unit, The Second Internal Medicine Department, Aristotle University Medical School, Hippokrateio General Hospital, Thessaloniki 54642, Greece. elengigi@auth.gr.
World journal of gastroenterology
|March 22, 2024
概括
乙型肝炎 (HBV) 和乙型肝炎 (HDV) 的同时感染可能导致严重的肝病. 病毒性肝炎和自身免疫性肝炎 (AIH) 之间的联系需要进一步研究,以指导同时感染患者的治疗.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
背景情况:
- 乙型肝炎病毒 (HBV) 和乙型肝炎病毒 (HDV) 的联合感染影响全球数以百万计的人,导致肝硬化和肝细胞癌等严重的肝病.
- 病毒性肝炎和自身免疫性疾病之间存在已知的相关性,在HBV/HDV同时感染的患者中检测到自身抗体.
- 临床上显著的自身免疫性肝炎 (AIH) 很少在高强度病毒感染的个体中报告,特别是那些接受基化干扰素治疗的人,这引发了诊断和病因问题.
研究的目的:
- 研究HBV/HDV联合感染和自身免疫性肝炎 (AIH) 之间的复杂关系.
- 为了解决关键的未回答的问题,关于自身免疫和"自身免疫类型"肝炎之间的区别在这个患者群体.
- 确定HBV或HDV是否会诱导自身免疫,以及先前对HDV进行的基化干扰素治疗是否会导致AIH.
主要方法:
- 对HBV/HDV联合感染和AIH现有文献和案例研究的审查.
- 对同时感染患者的自身抗体概况的分析.
- 检查与同时感染和AIH患者的基化干扰素和免疫抑制剂治疗结果.
主要成果:
- 在患有HDV感染的患者中,很少有临床显著AIH的记录,通常与基化干扰素治疗有关.
- 在免疫抑制治疗后,在感染HBV的AIH患者中发现HDV感染.
- 在HBV/HDV联合感染的背景下,区分真实AIH与"自身免疫性"肝炎的不确定性.
结论:
- 需要澄清,以区分AIH与HBV/HDV共感染个体的"自身免疫性"肝炎.
- 进一步的研究是必不可少的,以确定HBV与HDV在诱导自身免疫性方面的致病作用.
- 阐明这些问题对于选择适当的疗法至关重要,包括新型抗病毒药物,如布莱维尔提德或免疫抑制剂,用于管理患有HDV和AIH的患者.
相关概念视频
Autoimmune Disorders
430
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
430
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Chronic Pancreatitis II: Collaborative Care
86
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
86
Gastritis III: Clinical Manifestations and Management
235
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
235
Acute Pancreatitis II: Clinical Manifestations and Management
122
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
122
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


